CHRS
Coherus Biosciences Inc

5,135
Mkt Cap
$244.32M
Volume
1.16M
52W High
$2.62
52W Low
$0.71
PE Ratio
-1.12
CHRS Fundamentals
Price
$1.63
Prev Close
$1.69
Open
$1.69
50D MA
$1.80
Beta
1.79
Avg. Volume
1.99M
EPS (Annual)
-$1.45
P/B
3.24
Rev/Employee
$286,884.35
$48.58
Loading...
Loading...
News
all
press releases
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.
Coherus Oncology (NASDAQ:CHRS) used its presentation at the Citizens Life Sciences Conference to outline its transition into what CEO Denny Lanfear described as an innovative oncology company focused...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen
Wall Street Zen raised Coherus Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1d ago
News Placeholder
Coherus Oncology Q4 Earnings Call Highlights
Coherus Oncology (NASDAQ:CHRS) outlined progress on its transition to an innovative oncology company during its fourth-quarter and full-year 2025 earnings call, highlighting a growing commercial base...
MarketBeat·6d ago
News Placeholder
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Coherus Oncology (NASDAQ:CHRS - Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of...
MarketBeat·6d ago
News Placeholder
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday
Coherus Oncology (NASDAQ:CHRS) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·13d ago
News Placeholder
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +11.11% and +0.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of -40.71% and +0.66%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200-Day Moving Average - What's Next?
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving Average - Here's Why...
MarketBeat·19d ago
News Placeholder
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of +350.00% and +1.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
<
1
2
...
>

Latest CHRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.